NCT02457221 - A Study to Compare the Efficacy and Safety of Tacrolimus Capsules and Cyclophosphamide Injection in Treatment of Lupus Nephritis | Biotech Hunter

Enrollment

314

Participants

Timeline

Start Date

March 10, 2015

Primary Completion Date

September 10, 2018

Study Completion Date

September 10, 2018

Conditions

Lupus Nephritis

Interventions

DRUG

Tacrolimus capsules

oral

DRUG

Cyclophosphamide injections

intravenous injection

DRUG

Prednisone

oral

Trial Locations (35)

Unknown

Site CN00043, Hefei

Site CN00030, Beijing

Site CN00034, Beijing

Site CN00041, Xiamen

Site CN00056, Guangzhou

Site CN00017, Shenzhen

Site CN00045, Liuzhou

Site CN00037, Nanning

Site CN00038, Nanning

Site CN00020, Shijiazhuang

Site CN00047, Shijiazhuang

Site CN00028, Zhengzhou

Site CN00023, Wuhan

Site CN00024, Wuhan

Site CN00027, Changsha

Site CN00050, Changsha

Site CN00012, Nanjing

Site CN00013, Nanjing

Site CN00025, Nanjing

Site CN00049, Wuxi

Site CN00026, Changchun

Site CN00042, Changchun

Site CN00005, Dalian

Site CN00018, Shenyang

Site CN00019, Shenyang

Site CN00032, Qingdao

Site CN00001, Shanghai

Site CN00014, Shanghai

Site CN00015, Shanghai

Site CN00052, Taiyuan

Site CN00002, Chengdu

Site CN00003, Chengdu

Site CN00021, Tianjin

Site CN00044, Ürümqi

Site CN00010, Hangzhou

All Listed Sponsors

lead

Astellas Pharma China, Inc.

INDUSTRY